Table 3

Variables from a multivariate analysis describing the probability of developing severe aGVHD

VariableNo.RR95% CIP
Diagnosis 57    
    Non-CML  1   
    CML  2.54 1.06-6.04 .036 
CD8+ T-cell dose 57    
    < 47.7 × 106  1   
    > 47.7 × 106  1.7 0.75-3.86 .2 
Total iNKT-cell dose 57    
    > 0.057 × 106  1   
    < 0.057 × 106  1.36 0.58-3.18 .48 
CD4+ iNKT-cell dose 57    
    > 0.026 × 106  1   
    < 0.026 × 106  5.51 0.87-35.1 .07 
CD4− iNKT-cell dose 57    
    > 0.031 × 106  1   
    < 0.031 × 106  4.27 1.68-10.85 .0023 
VariableNo.RR95% CIP
Diagnosis 57    
    Non-CML  1   
    CML  2.54 1.06-6.04 .036 
CD8+ T-cell dose 57    
    < 47.7 × 106  1   
    > 47.7 × 106  1.7 0.75-3.86 .2 
Total iNKT-cell dose 57    
    > 0.057 × 106  1   
    < 0.057 × 106  1.36 0.58-3.18 .48 
CD4+ iNKT-cell dose 57    
    > 0.026 × 106  1   
    < 0.026 × 106  5.51 0.87-35.1 .07 
CD4− iNKT-cell dose 57    
    > 0.031 × 106  1   
    < 0.031 × 106  4.27 1.68-10.85 .0023 

“Best” model from a backward-stepping procedure that included the variables found significant at the P < .1 level in univariate analyses: CML diagnosis, CD8+ T-cell dose, total iNKT-cell dose, CD4+ iNKT-cell dose, and CD4− iNKT-cell dose.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal